Filing Details

Accession Number:
0001567619-22-004608
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-02-15 16:25:34
Reporting Period:
2022-02-11
Accepted Time:
2022-02-15 16:25:34
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1623715 Imago Biosciences Inc. IMGO Pharmaceutical Preparations (2834) 454915810
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1861067 G. Laura Eichorn C/O Imago Biosciences, Inc.
329 Oyster Point Blvd, 3Rd Floor
South San Francisco CA 94080
See Remarks No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-02-11 4,000 $1.52 211,737 No 4 M Direct
Common Stock Disposition 2022-02-11 4,000 $23.61 207,737 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2022-02-11 4,000 $0.00 4,000 $1.52
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
34,595 2029-04-09 No 4 M Direct
Footnotes
  1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
  2. The transaction was executed in multiple trades in prices ranging from $23.50 to $23.74, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  3. One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from April 10, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.